Turnstone Biologics Corp.

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

The number of biopharmaceutical companies that have gone public in the US in 2024 has now beat the 2023 total of 21 with the 10 October initial public offerings by Upstream Bio Inc. and CAMP4 Thera

Novartis AG outlined the details of its spin-off plans for its generics and biosimilars business Sandoz on 18 August, revealing the financial terms for the big pharma’s shareholders and the date of t

The number of initial public offerings in the US by biopharmaceutical companies in 2023 may be able to at least match the number of IPOs in 2022 now that another company has made its stock market debu